CN1593454A - Magnesium, potassium and calcium mixture and its usage - Google Patents
Magnesium, potassium and calcium mixture and its usage Download PDFInfo
- Publication number
- CN1593454A CN1593454A CN 200410040047 CN200410040047A CN1593454A CN 1593454 A CN1593454 A CN 1593454A CN 200410040047 CN200410040047 CN 200410040047 CN 200410040047 A CN200410040047 A CN 200410040047A CN 1593454 A CN1593454 A CN 1593454A
- Authority
- CN
- China
- Prior art keywords
- magnesium
- calcium
- potassium
- parts
- mixture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a magnesium, potassium and calcium mixture and its use thereof, characterized in that it is prepared from the following raw materials (by weight parts), magnesium 120-240 parts, potassium 37.5-112.5 parts, calcium 120-240 parts, microelement 15.5-24.5 parts, vitamin 160-220 parts, and folic acid 100-150 parts.
Description
One, technical field
The present invention relates to a kind of magnesium, potassium and calcium mixture and uses thereof, is that main multiple disease has important benefit at the control cardiovascular and cerebrovascular disease, belongs to the Western medicine preparation field.
Two, background technology
Magnesium, potassium and calcium all is the needed by human macroelement, heart, blood vessel, nerve, skeletal muscle all there are important effect, replenish the calcium now to everybody knows, yet replenish the calcium if only know, and the words of magnesium supplement not, the danger of high-calcium low-magnesium then can take place, and body magnesium deficiency then can be facilitated calcification, and magnesium supplement can prevent calcification, aging, there is not magnesium, calcium can not fully absorb, and magnesium is called as a nutrient that passes into silence
Domesticly do not see the magnesium, potassium and calcium mixture, aestheticism Guoan clever is sold the product calcium magnesium slice directly to households, is the product that domestic unique magnesium calcium at present lumps together.The happy power of U.S.'s product contains calcium magnesium, also has the motassium magnessium aspartate (domestic also have the family of producing imitated) of Hungary's import, and the calcium magnesium slice that more than removes An Li company is medicine, and the problem of existence is:
1. general content of magnesium owes low:
Every of aspartic acid magnesium sheet is 2.8-11.8mg only; Every of magnesium gluconate is 58.6mg; The magnesium ion level is low then not to reach the effect that prevents and treats disease, studies show that as U.S. expert: the magnesium 174mg that need take in every day is above could stabilizing blood pressure.
2. it is undesirable to fill a prescription
The happy power of the calcium magnesium slice and the U.S. of peace clever does not all contain potassium, and potassium is the important ion of keeping cardiac rhythm, helps the absorption of magnesium calcium simultaneously.
In the aspartic acid magnesium sheet except that content is low, calcic not.
Three, summary of the invention
The objective of the invention is provides a kind of magnesium, potassium and calcium mixture and uses thereof at the deficiencies in the prior art, be characterized in adopting mixture that magnesium, potassium and calcium and trace element and vitamin compatibility make that arteriosclerosis, coronary heart disease, hypertension and osteoporosis are had the new recipe of health care and therapeutical effect, this prescription than the compatibility of existing similar prescription more comprehensively, more reasonable, clinical efficacy is better.
The present inventor is according to patients' such as long-term utilization head injury treated with magnesium preparation arrhythmia, coronary heart disease, hypertension experience and clinical serial scientific research result, Shao Meizhen " magnesia mixture is prevented and treated the clinical series of studies of cardiovascular disease " in July, 1992, Huaxi Medical Univ.Shao Meizhen chief editor " basis of magnesium and clinical " published in Sichuan science and technology publishing house in 1996, this is the medical science monograph of domestic first magnesium, thereby develops content higher magnesium preparation and magnesium, potassium and calcium mixture and contain the trace element of cooperative effect, the effect of vitamin and mutual substantial connection:
Magnesium and potassium are in close relations, this is very important to doctor and patient, only about half of potassium hangs down patient, and magnesium also lacks, and low potassium state, simple kalium replenishment is difficult for correcting, add just easily correction of magnesium, do not have enough magnesium, human body can not make potassium move in the cell, this is to keep health, and it is very important keeping the heart normal function.
The relation of magnesium and calcium is that calcium absorption needs magnesium, does not have enough magnesium, and calcium can accumulate in soft tissue to be caused arthritis, be deposited on blood vessel wall and then promote arteriosclerosis.Cardiovascular and cerebrovascular disease and osteoporosis are the highest diseases of current sickness rate, with magnesium, calcium relation is arranged all, experimental results show that, the interior calcium of companion cell increases during magnesium deficiency, can not squeeze out calcium in cell by the activity of magnesium dependency calcium-ATP enzyme, the result causes the energy sink-mitochondrion and the histiocyte calcification thereof of cell, so the necessary balance of magnesium and calcium is also answered magnesium supplement when replenishing the calcium, prevent low magnesium high calcium; The high hazardness of ratio of calcium/magnesium, except that causing the arterial wall calcification, to the paathogenic factor in the arteriosclerosis forming process, as platelet aggregation, thrombosis also is deleterious, known calcium has certain effect in coagulation process, ratio as calcium magnesium increases, and then increases the danger of blood clotting and thrombosis, and magnesium has anticoagulation, magnesium antagonism calcium, and the proteic dissolving of fortifying fibre.Everybody craves for healthy health, not sick, all wish own young, long-lived, retarding ageing, the aging cell that means, the organ pipe calcification, calcification can cause many diseases, the arterial wall calcification is that arteriosclerotic factor takes place, the brain cell calcification then can cause dementia, hypomnesis, brain function is low inferior, the formation of calcification takes place, be relevant with the biochemistry state of individuality, calcium and magnesium all are the indispensable elements of body, replenish the calcium now and know for everybody, if yet only know and replenish the calcium, and the words of magnesium supplement not, the danger of high-calcium low-magnesium then can take place, calcium and the magnesium ratio in somatic cell is your biochemistry age, and body magnesium deficiency then can be facilitated calcification, and magnesium supplement can prevent calcification, aging.
Purpose of the present invention is realized that by following technical measures wherein said raw material umber is parts by weight except that specified otherwise.
120～240 parts in magnesium
37.5～112.5 parts in potassium
120～240 parts of calcium
15.5～24.5 parts of trace element
160～220 parts of vitamin
100～150 parts in folic acid
Wherein trace element is boron, zinc, copper, silicon and strontium, and vitamin is VitD-3, Vit-K and Vit-B
6
Beyond demagging, potassium, the calcium, boron, zinc, copper, silicon, strontium, Vit-K VitD Vit-B6 etc. all help sclerotin and form, and sketch in following:
Boron: also can promote calcium absorption, synthetic 17B-estradiol and 1.25 dihydroxy VitD3 are needed; And the endogenous estrogen level that can raise; Have antitumaous effect, boron is very important to the healing of prevention of osteoporosis and the fracture that causes.
Zinc: be normal osteoplastic substrate, it also strengthens the biochemical action of Vit-D, and the senile osteoporosis patient, serum zinc also reduces.
Copper: supplementation with copper can suppress bone resorption, and copper is the composite factor of lysyl oxidase, by the cross link of glue unit strand, strengthens connective tissue.
Silicon:, strengthen connective tissue matrix by the cross link of glue unit strand.Skull takes place and intersects unusually and the thigh bone attenuation in the chicken that lacks silicon.
Strontium: relative with tooth more at bone, zoopery shows can reduce bone resorption, and mending afterwards to the osteoporosis patient, osteodynia obviously alleviates, X-ray examination improves.
Vit-K:Vit-K also is that synthetic Bone Gla protein is needed, and Bone Gla protein is the protein in the bone, is and the blended protein of calcium crystal, to needing in bone formation, the reparation.Osteoporosis blood K for each person only is 35% of a matched group.After osteoporosis patient mends Vit-K, reduce urine calcium and lose.
Vit-D: be that intestinal absorption calcium is needed, but need change bioactive 1.25 hydroxylation Vit-D3 into.Magnesium and boron can promote this transformation.
Vit-B
6: strengthen connective tissue intensity, nation helps and destroys homocysteine etc.
Folic acid: work in the homocysteine associated metabolic, folic acid can not raise by the aloof from politics and material pursuits cysteine of hyperamization completely, and bone is had seondary effect.
To be the conventional method that adopts Western medicine preparation make preparations such as tablet or capsule with magnesium oxide, potassium chloride and calcium carbonate or calcium ascorbate and trace element, vitamin with the magnesium, potassium and calcium mixture, and this is that this area pharmaceutical technology personnel know.
The magnesium, potassium and calcium mixture is mainly used in the health care and the treatment of cardiovascular and cerebrovascular disease and osteoporosis.
The present invention has following advantage:
1, the magnesium, potassium and calcium mixture can be used as food, takes for a long time, can play retarding ageing, the beginning of the disease that slows down, and prevents and treats frequently-occurring diseases such as arteriosclerosis, osteoporosis.
2, to arrhythmia, hypertension, chronic heart failure during with diuretic electrolyte supplement, muscle spasm, premenstrual syndrome, chronic bronchitis inflammation, migraine, fatigue syndrome, constipation etc. preventive and therapeutic effect is arranged.
3, magnesium, potassium and calcium mixture, can be when kalium replenishment calcium magnesium supplement simultaneously, in view of people to calcium, the existing understanding of potassium, but magnesium is also lacked understanding, can initiatively not remove magnesium supplement, the magnesium, potassium and calcium mixture has then solved and has replenished the calcium, filled magnesium potassium the time.
4, the clinical and lab testing result of magnesium, potassium and calcium mixture:
(1) prevents and treats arrhythmia: once, controlled behind the oral administration magnesium, potassium and calcium mixture to routine rooms 52, ventricular premature contraction, sinus tachycardia, short battle array property chamber tachycardia.Do not control through the anti-arrhythmic amiodarone as a routine chronic premature beat yet, and added one week of magnesium, potassium and calcium mixture, eliminate chronic premature beat; One routine myocarditis patient, sinus tachycardia was once lived certain hospitalize, and the back heart beating of leaving hospital is also fast, and one minute 102 times, outpatient service, through obeying the magnesium, potassium and calcium sheet 5 days, heart rate has promptly slowed down.
(2) allevating angina pectoris, to the effect of coronary heart disease 52 examples:
Allevating angina pectoris: through clothes magnesium, potassium and calcium mixture, treating a week is obvious allevating angina pectoris to 44 examples, with before the treatment relatively, no longer feel angina pectoris after the movable fatigue, but nitric acid preparation decrement or withdraw.
To the blood fat effect: through clothes magnesium, potassium and calcium two weeks of mixture, the decline average is 1.01mmol/L to the 18 routine triglyceride persons of increasing.
Echocardiography: improve left chamber contractile function, increase to 62.5% as ejection fraction 48.59, cardiac output 4.02 increases to 5.29L/ and divides whenever that the amount of fighting 57.09 increases to 70.18ml, all obviously increases.
(3) can reduce and stable hypertension: once to 52 routine oral two weeks of magnesium, potassium and calcium mixture of essential hypertension, blood pressure was low when obeying depressor, and wherein 20 examples reduce depressor, withdrew depressor 3 to 5 before finishing the course of treatment, and blood pressure does not go up yet; 20 routine mild hypertensions are only obeyed the magnesium, potassium and calcium mixture, withdraw depressor, and 16 examples are effective as a result, and 4 examples are invalid.
Above presentation of results, the magnesium, potassium and calcium mixture can be treated the mild hypertension patient; The auxiliary treatment of severe hypertension can reduce the depressor consumption in can be used as.
(4) chronic asthmatic tracheitis is taken a turn for the better: a middle-aged male, give clothes magnesium, potassium and calcium mixture sheet after two weeks because of the treatment angina pectoris, glad informs, except that angina pectoris takes a turn for the better, has not upstairs also breathed heavily.
(5) to migraine 8 examples, through clothes magnesium, potassium and calcium after one week, no longer morbidity, low dose then need be obeyed and just taken effect in two weeks.
Four, the specific embodiment
Below by embodiment the present invention is carried out concrete description; be necessary to be pointed out that at this present embodiment only is used for the present invention is further specified; can not be interpreted as limiting the scope of the invention, the person skilled in the art in this field can make some nonessential improvement and adjustment according to the content of the invention described above.
One, embodiment: the magnesium, potassium and calcium mixture is in every grain prescription compatibility of medicines amount:
The compatibility component of table 1 magnesium, potassium and calcium mixture
*
Magnesium oxide potassium chloride calcium carbonate
B Zn Cu Si S VitD-3
Numbering (Mg
++) (K
+) (Ca
++)
Mg/ sheet mg/ sheet mg/ sheet mg/ sheet mg/ sheet mg/ sheet
Mg/ sheet mg/ sheet mg/ sheet
1 240 112.5 120 1.0 10 1.0 2.5 1 150
2 120 75 240 1.5 15 1.5 3.3 1.5 180
3 100 37.5 240 2.0 15 2.0 3.5 2.0 200
Vit-K Vit-B
6Folic acid
The crowd of being suitable for
Mg/ sheet mg/ sheet mg/ sheet
55 100 based on the cardiovascular diseases
10 10 150 based on general health care
10 10 100 based on osteoporosis
*As synthetic with Aspartic Acid, then magnesium, potassium content should reduce, because of the bioavailability height.
Two, application example
1, the clinical effectiveness of embodiment 1 compatibility
Table 2 pair hypertensive effect
Behind the preceding blood pressure depressor of embodiment 1 prescription medication
With P behind first prescription
A slice, three times on the one mmHg mmHg
Magnesium, potassium and calcium mixture 52 examples about 162/102 about 152/94 about 142/85＜0.01
Magnesium, potassium and calcium mixture 20 examples about 150/100 (not using depressor) about 140/90＜0.01
Table 3 pair coronary heart disease, curative effect to treat angina pectoris and matched group are relatively
The produce effects invalid total effective rate that takes a turn for the better
Example number % example number % example number % %
Magnesium, potassium and calcium mixture 54 examples 44 81 8 14.8 2 3.7 96 x
2=41.867
Conventional therapy 27 examples 2 7.4 14 52 11 40 59 P＜0.005
Table 4 pair ARR effect
It is invalid that produce effects takes a turn for the better
Ventricular premature contraction 7 examples 511
The chamber is bigeminy rate 10 examples 811 early
Sinus tachycardia 5 examples 500
2, results of laboratory shows scalable blood fat, anticoagulant and reduction platelet adhesion rate.
The effect of table 5 pair blood fat
TG (19 example) LDL (18 example)
Clothes back P before the P clothes of clothes back before the clothes
Embodiment 1 prescription 3.24 ± 1.07 2.47 ± 0.88＜0.01 4.27 ± 0.44 3.47 ± 1.03＜0.01
Routine administration contrast 2.78 ± 1.074 2.82 ± 1.18＞0.5 4.02 ± 0.41 3.76 ±＞0.5
Table 6 anticoagulation is to thromboxane B2,6-ketone PGF
1aEffect
Thromboxance B
2(21 example) 6 ketone PGF1a (32 example) blood resists plain B
2The ratio of/6 ketone PGF1a (21 example)
Take medicine preceding 410.24 ± 152.07 24.48 ± 9.41 18.75 ± 10.21
Take medicine back 249.40 ± 93.48 30.82 ± 21.26 10.09 ± 9.85
P ＜0.01 ＜0.025 ＜0.001
Table 7 reduces platelet adhesion rate
Mean % clothes back mean % P before the platelet adhesion rate clothes
Embodiment 1 prescription 22 examples 47.22 ± 10.34 35.66 ± 11.65＜0.001
Routine administration 15 examples 40.78 ± 7.61 42.53 ± 7.47＞0.5
Claims (2)
1, a kind of magnesium, potassium and calcium mixture is characterized in that it is made by the material combination of following weight parts,
120～240 parts in magnesium
37.5～112.5 parts in potassium
120～240 parts of calcium
15.5～24.5 parts of trace element
160～220 parts of vitamin
100～150 parts in folic acid
Wherein trace element is boron, zinc, copper, silicon and strontium, and vitamin is VitD-3, Vit-K and Vit-B
6
2, the purposes of magnesium, potassium and calcium mixture according to claim 1 is characterized in that this magnesium, potassium and calcium mixture is mainly used in the health care and the treatment of cardiovascular and cerebrovascular disease and osteoporosis.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040047 CN1284541C (en) | 2004-06-22 | 2004-06-22 | Magnesium, potassium and calcium mixture and its usage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200410040047 CN1284541C (en) | 2004-06-22 | 2004-06-22 | Magnesium, potassium and calcium mixture and its usage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1593454A true CN1593454A (en) | 2005-03-16 |
| CN1284541C CN1284541C (en) | 2006-11-15 |
Family
ID=34664442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200410040047 Expired - Fee Related CN1284541C (en) | 2004-06-22 | 2004-06-22 | Magnesium, potassium and calcium mixture and its usage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1284541C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111787928A (en) * | 2017-07-31 | 2020-10-16 | 慧创骨科药品有限公司 | Multi-mineral supplement for increasing bone density |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI742119B (en) * | 2017-07-28 | 2021-10-11 | 香港商慧創骨科藥品有限公司 | Multi-mineral supplement for improved bone density |
-
2004
- 2004-06-22 CN CN 200410040047 patent/CN1284541C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111787928A (en) * | 2017-07-31 | 2020-10-16 | 慧创骨科药品有限公司 | Multi-mineral supplement for increasing bone density |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1284541C (en) | 2006-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1026064C (en) | Preparation process for composite inhibiting activated | |
| CN1117874A (en) | Nasally administrable compositions | |
| CN1903220A (en) | Health-care food with function of improving skeletal density and its prepn. method | |
| CN1947600A (en) | Sun-rays proof beauty-care beverage | |
| CN101049157A (en) | Functional health food for preventing osteoporosis | |
| CN105079028A (en) | Health care product capable of improving bones and joints and preparation method of health care product | |
| CN1883286A (en) | A tea milk and method for preparing same | |
| CN1284541C (en) | Magnesium, potassium and calcium mixture and its usage | |
| CN1679615A (en) | Compound infantile energy mistura soluble vitamin preparation and use thereof | |
| CN1270624C (en) | Pollen, bee milk food and its preparation method | |
| CN1785330A (en) | Medicine for treating high blood pressure and its preparation method | |
| CN104382033A (en) | Compound protein tabletted candy and preparation method thereof | |
| CN1927059A (en) | Buccal tablets produced with peanut and red date, and method for making same | |
| CN1840176A (en) | Sublingual tablet of natural hirudin | |
| CN1686488A (en) | Medicine for treating malignant tumour and its production method | |
| CN1283228C (en) | Shower bath agent with tibetan medicine | |
| CN1965933A (en) | Medicated tea for lowering blood pressure and method for preparing same | |
| CN1541568A (en) | Sea cucumber slice and its preparation method | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1679608A (en) | Compound preparation of inosine, triphosphoadenosine and vitamin C and use thereof | |
| CN1785240A (en) | Dripping pills used for treating coronary heart disease and its prepn. method | |
| CN1772135A (en) | Spur eliminating antiphlogistic plaster and its prepn | |
| CN1954835A (en) | Sea-buckthorn plant preparation and its preparation method | |
| CN1663600A (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| CN1634130A (en) | Composition for preventing and treating women postmenopausal osteoporosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HUAXI HOSPITAL ATTACHED TO SICHUAN UNIV. Free format text: FORMER OWNER: SHAO MEIZHEN Effective date: 20090612 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20090612 Address after: No. 37, Guoxue lane, Chengdu, Sichuan, Wuhou District Patentee after: West China Hospital of Sichuan University Address before: West China Hospital of Sichuan University, Sichuan, Chengdu Province, China Patentee before: Shao Meizhen |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20061115 Termination date: 20110622 |